Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 1/20 | 0.50 |
| ▸ | F10 | P00742 | 3/20 | 0.47 |
| ▸ | ACE | P12821 | 6/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 4/20 | 0.45 |
| ▸ | RAMP1 | O60894 | 2/20 | 0.43 |
| ▸ | CALCRL | Q16602 | 2/20 | 0.43 |
| ▸ | XIAP | P98170 | 2/20 | 0.42 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.42 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.42 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6797136 | 0.85 | F10 (0.46) | NPY1RF10ACEMMEAPP | |
| SCHEMBL5639922 | 0.84 | NPY1R (0.39) | NPY1RF10ACEMMEAPP | |
| SCHEMBL5637435 | 0.83 | NPY1R (0.58) | NPY1RACEMMEAPPSRC | |
| SCHEMBL5639916 | 0.82 | NPY1R (0.39) | NPY1RF10ACEMMEAPP | |
| SCHEMBL7950295 | 0.79 | SRC (0.67) | NPY1RAPPSRCTPSAB1TPSD1 | |
| SCHEMBL21143944 | 0.78 | ACE (0.44) | NPY1RF10ACEMMEAPP | |
| SCHEMBL5638958 | 0.78 | ACE (0.44) | NPY1RF10ACEMMEAPP | |
| SCHEMBL5638930 | 0.78 | SIRT1 (0.40) | NPY1R | |
| SCHEMBL5637803 | 0.78 | SRC (0.52) | NPY1RACEMMEAPPSRC | |
| SCHEMBL5638151 | 0.78 | SRC (0.49) | NPY1RACEMMEAPPSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220856-B2 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-22 | — | — | US | disclosed |
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | CCR5, CXCR3, CCR2 | NPY1R 265/4885F10 4667/4885ACE 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.